Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia

• DOI: 10.1160/th11-05-0340
• Publication Date: 2011-09-22T12:59:51Z
• Authors: Céline Chauleur; Nicolas Molinari; Pierre Marès; Pascale Fabbro-Peray; Isabelle Quéré; Jean-Yves Lefrant; Bassam Haddad; Michel Dauzat; Jean-Christophe Gris
• Keywords: Enoxaparin sodium

Summary dministration of heparin in the secondary prevention placental vascular complications is still experimental. In women with a previous severe pre-eclampsia, we investigated effectiveness enoxaparin, low-molecular-weight heparin, preventing these complications. Between January 2000 and 2010, 224 from NOHA First cohort, pre-eclampsia but no foetal loss during their first pregnancy negative for antiphospholipid antibodies, were randomised to either prophylactic daily dose enoxaparin starting positive test (n=112), or (n=112). The primary outcome was composite at least one following: abruptio placentae, birthweight ≤5th percen-tile, after 20 weeks. Enoxaparin associated lower frequency outcome: 8.9% (n=10/112) vs. 25 % (28/112), p=0.004, hazard ratio = 0.32, 95% confidence interval (0.16–0.66), p=0.002. safe, obvious side-effect, thrombocytopenia nor major bleeding event excess. This pilot study shows that given early second decreases occurrence pregnancy. controlled NOH-PE trial